Usage Examples
- The trial is double-blind, so the bioanalytical group works off a code list under an SOP that keeps assignments away from the clinical team.
- We had one emergency unblinding at site 04; it is in the deviation log and will be explained in the CSR.
- Blinding is not feasible for the surgical arm, so the endpoint adjudication committee stays blinded to assignment instead.
What is Blinding?
Blinding is the bias-control measure in a clinical trial that conceals treatment assignment from subjects, investigators, or analysts, distinct from randomisation, which determines how subjects are assigned rather than who knows the assignment.
Blinding exists because knowing the assignment changes behaviour long before anyone reaches the analysis. ICH E9 names the leak points: recruitment and allocation of subjects, their subsequent care, subject attitudes to the treatments, endpoint assessment, handling of withdrawals, and exclusion of data from analysis. Blinding is aimed at preventing identification of the treatments until every one of those opportunities for bias has passed.
Blinding governs who may know the assignment, not how the assignment was made. Double-blind covers subjects plus any investigator or sponsor staff involved in treatment or clinical evaluation, including anyone determining eligibility or evaluating endpoints. Blinding does not cover randomisation, the analysis plan, or staff deliberately unblinded under SOP such as bioanalytical scientists, auditors, and serious-adverse-event reporters, and it ends at the planned unblinding once data are clean.
Blinding is executed through treatments that cannot be distinguished by appearance or taste, a double-dummy scheme when the dosing patterns differ, an emergency code-break the investigator can reach from day one, and SOPs restricting treatment-code access while the database is being cleaned. Blinding failures are not buried: every intentional or unintentional break is reported and explained at the end of the trial.
Not to be confused with
- Randomisation
- randomisation decides how subjects are assigned; blinding decides who is allowed to know. A trial can be fully randomised and completely open-label, and ICH E9 treats them as two separate subsections.
- Allocation concealment
- concealment protects the upcoming assignment before a subject is enrolled, which is why single-blind and open-label trials still use centralised randomisation. Blinding protects knowledge of the assignment after it is made.
- Open-label
- open-label is the deliberate absence of blinding, not a broken blind. It is a design choice that shifts the burden onto objective endpoints, blinded assessors, and other documented bias controls.
- Double-dummy
- a technique for reaching double-blind conditions when two treatments cannot be made to look alike, such as different dosing schedules. It is a means of achieving blinding, not a level of it.
The obligations sit in the IND protocol, the trial conduct rules, and the efficacy evidence standard.
What you must do
- 1Describe in the IND protocol the study design, the kind of control group, and the methods used to minimize bias on the part of subjects, investigators, and analysts21 CFR 312.23(a)(6)(iii)(d)
- 2Take adequate measures to minimize bias on the part of the subjects, observers, and analysts of the data in any study offered as adequate and well-controlled21 CFR 314.126(b)(5)
- 3For a placebo concurrent control, use an inactive preparation designed to resemble the test drug as far as possible, so the blind survives administration21 CFR 314.126(b)(2)(i)
- 4Maintain the blind so that treatments cannot be identified until every listed opportunity for bias, through endpoint assessment and data exclusion, has passedICH E9 Section 2.3.1
- 5Be capable from the start of the trial of emergency unblinding without undue delay, and promptly document and explain any premature unblinding to the sponsorICH E6(R3) Section 2.11
Common mistakes
Calling a trial double-blind when sponsor staff can see the codes
ICH E9's definition reaches anyone determining eligibility, evaluating endpoints, or assessing protocol compliance. Bioanalytical, audit, and safety-reporting staff may be unblinded, but only under SOPs that guard against dissemination of treatment codes. Without those SOPs the protocol and the CSR both overstate the design.
Building an emergency code-break that is slow or discouraged
the investigator must be able to unblind without undue delay and hindrance from the first day of the trial. Gating the mechanism behind sponsor approval to protect the data is a participant-safety finding, and the obligation is to document and explain the break, not to prevent it.
Leaving the blind unprotected during data cleaning
access to the treatment code has to stay restricted until the database is released for analysis. A team that sees assignments while it is still deciding on analysis sets, exclusions, and outlier handling has produced results a reviewer can discount, whatever the p-value says.
When This Matters
- The trial is double-blind, so the bioanalytical group works off a code list under an SOP that keeps assignments away from the clinical team.
- We had one emergency unblinding at site 04; it is in the deviation log and will be explained in the CSR.
- Blinding is not feasible for the surgical arm, so the endpoint adjudication committee stays blinded to assignment instead.
Frequently Asked Questions
Double-blind means neither the subject nor any investigator or sponsor staff involved in treatment or clinical evaluation knows the assignment, including anyone determining eligibility, evaluating endpoints, or assessing compliance. Single-blind means only one side is unaware, usually the subject. ICH E9 treats double-blind as the optimal approach and single-blind as the fallback.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Clinical Workflows
Track clinical trial regulations across global markets
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
